CRISPR Therapeutics' GAAP net income for 9M 2021 was $218.909 million, against a loss of $241.826 million in the previous year. Revenue increased multiple times to $902.064 million from $0.349 million a year earlier.
CRISPR Therapeutics' GAAP net income for 9M 2021 was $218.909 million, against a loss of $241.826 million in the previous year. Revenue increased multiple times to $902.064 million from $0.349 million a year earlier. 
ir.crisprtx.com
English (US) 